Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 3

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 3
---
 securities offered by this prospectus. See “Plan of Distribution” section of this prospectus for more information regarding these arrangements. There is no minimum number of
shares of common stock or pre-funded warrants or minimum aggregate amount of proceeds that is a condition for this offering to close.
We may sell fewer than all of the shares of common stock and pre-funded warrants offered hereby, which may significantly reduce the amount
of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered
hereby. In addition, because there is no escrow account and no minimum number of securities or amount of proceeds, investors could be
in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended
uses of the proceeds as described in this prospectus.

|                                    |     | Per Share and Warrant |       |     | Per Pre-Funded Warrant and Warrant |       |     | Total |           |
|:-----------------------------------|:----|:----------------------|------:|:----|:-----------------------------------|------:|:----|:------|----------:|
| Public offering price              |     | $                     | 0.900 |     | $                                  | 0.899 |     | $     | 4,500,000 |
| Placement agent fees(1)            |     | $                     | 0.056 |     | $                                  | 0.050 |     | $     |   281,250 |
| Proceeds, before expenses to us(2) |     | $                     | 0.844 |     | $                                  | 0.849 |     | $     | 4,218,750 |

| (1) | We have agreed to (i) pay                                                                                                             
 the placement agent a cash fee equal to 6.25% of the aggregate gross proceeds raised at the closing of this offering and (ii) issue   
 warrants to the placement agent exercisable for a number of shares of common stock equal to 4.0% of the total number of shares of     
 common stock issued in this offering. We have also agreed to reimburse the placement agent for certain expenses and closing costs.    
 See “Plan of Distribution” for additional information and a description of the compensation payable                                   
 to the placement agent.                                                                                                               |
| (2) | Because there is no minimum                                                                                                           
 number of securities or amount of proceeds required as